Pharmacist-based deprescribing successfully reduced older adults’ exposure to anticholinergic drugs

Credit: Unsplash/CC0 Public Domain

Anticholinergics, a class of drugs commonly prescribed for depression, urinary incontinence and many other conditions common in the elderly, affect the brain by blocking acetylcholine, a neurotransmitter that affects memory. storage, alerting and planning skills. A new study from the Regenstrief Institute, Purdue University College of Pharmacy and Indiana University School of Medicine researchers found that the use of anticholinergics as a maintenance agent reduced the number of prescriptions of anticholinergics by 73 percent and reduced the number of use of these drugs by about 70 percent.

“Our new study is important, the first work is necessary, it allows us to test whether the comparison of these drugs has improved. clinical outcomes, “said Regenstrief Institute and Purdue College of Pharmacy member Noll Campbell, PharmD, MS, who led the new study to develop central drug delivery models to successfully transition patients to safer medications. not be easy. That the model of counting-between drugs works well would not surprise me because pharmacists are suited to the job. They are knowledgeable about medicine, often have close relationships with patients and are well trained to communicate with providers. “

The researchers created two different types of medical devices. The first, face-to-face model involves pharmacists meeting with and observing elderly patients seen in a geriatric hospital. The second model, which involved telephone outreach by pharmacists to elderly patients encouraging safe medication, was ineffective in reducing exposure to anticholinergics but was more effective than other methods, including doctors alert in. electronic health records (EHRs). Overall, these products reduced prescriptions for anticholinergics by 73 percent and reduced the use of these drugs by nearly 70 percent.

The study was published in Journal of the American Academy of Pharmacology.

Using the human-specific methods described in the JACCP document, Regenstrief researchers are currently conducting R2D2—an acronym for “Reducing the Risk of Dementia by Deprescribing” to determine whether the cognitive effects of anticholinergic drugs can be reversed. . In this study, which is currently recruiting patients, medical doctors are working with doctors and patients who use anticholinergics to identify and switch to safer alternative medications. Also, the trial observes the effects of the introduction of these drugs on anxiety, depression, pain, insomnia, and quality of life.

Challenges in decision-making and reducing the use of anticholinergic drugs

Additional information:
Noll L. Campbell et al, Prescribing Anticholinergics in Adults in Primary Care: Experience from Two Models and Effects on Continuous Exposure Measurements, Journal of the American Academy of Pharmacology (2022). DOI: 10.1002/jac5.1682

Its availability
Regenstrief Institute

hint: Pharmacist-based prescribing successfully deprescribes older adults’ risk of anticholinergic drugs (2022, July 21) Retrieved 21 July 2022 from -adults .html

This document is subject to copyright. Except for any bona fide transaction for research or investigation purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.

Pharmacist-based deprescribing successfully reduced older adults’ exposure to anticholinergic drugs Source link Pharmacist-based deprescribing successfully reduced older adults’ exposure to anticholinergic drugs

Related Articles

Back to top button